NCT02322619

Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions

An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Comparing With Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc. in Healthy, Adult Human Subjects Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Dr. Reddy's Laboratories Limited · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study in human subjects under fasting conditions.

Detailed description

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of moxifloxacin tablets 400 mg of Dr. Reddy's Laboratories Limited, comparing with Avelox ® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc. in healthy, adult, human subjects under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Moxifloxacin Tablets 400 mg	Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited

Timeline

• Start date: 2012-11-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2014-12-23
• Last updated: 2014-12-23